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Abstract
Aims/hypothesis Diabetes increases the risk of cardiovas-
cular disease (CVD) and heart failure, as well as other
serious complications, such as renal disease and depression.
However, these conditions are often present prior to
diabetes diagnosis. We sought to determine whether they
increase the risk of developing diabetes independent of
other risk factors.
Methods We identified 58,056 non-diabetic adults aged
≥30 years with no evidence of diabetes. Using electronic
medical records, we identified the presence of four
conditions at baseline (CVD, heart failure, renal disease
and depression) and then estimated diabetes incidence over
5 years separately for patients with and without each of
these conditions. Each incidence estimate was adjusted for
baseline values of age, sex, fasting glucose, body mass
index, systolic blood pressure, triacylglycerol, HDL-
cholesterol, smoking and the presence of the other three
conditions.
Results Patients with CVD were 35% (95% CI 23–48%)
more likely to develop diabetes after controlling for other
risk factors. Heart failure was independently associated
with an increase in diabetes incidence of 48% (95% CI 27–
73%), and depression was associated with a 10% (95% CI 2–
20%) increase. Chronic kidney disease was associated with a
non-significant risk increase of 10% (95% CI –2–25%).
Conclusions/interpretation Complications of diabetes are
more prevalent among patients who will ultimately develop
diabetes, and increase the risk of diabetes independently of
other known risk factors. The apparent bidirectional
relationships suggest that primary prevention of CVD may
also help prevent diabetes.





Patients with type 2 diabetes are at elevated risk of
cardiovascular disease (CVD), renal disease, heart failure
and depression, conditions that dramatically increase costs
and mortality relative to patients without diabetes [1].
Because these conditions are often already present when
diabetes is diagnosed [2], we examined whether cardiovas-
cular disease, renal disease, heart failure and depression
increase the risk of developing diabetes after accounting for
other known risk factors, including obesity, hyperglycae-
mia, hypertension and dyslipidaemia.
Methods
Kaiser Permanente Northwest (KPNW) is a closed group
model health maintenance organisation that provides
comprehensive medical care to approximately 475,000
individuals in the Portland, Oregon area of the USA. We
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identified 58,056 non-pregnant adults age 30 or older who
did not have a prior diagnosis of diabetes, had a fasting
plasma glucose test result <7 mmol/l, and also had blood
pressure, obesity (body mass index), HDL-cholesterol and
triacylglycerol measured in 2003 or 2004, and who
remained members of KPNW for at least 5 years following
the date that the last of the clinical variables mentioned
above was measured (index date). Those who died or left
the health plan were excluded. From electronic medical
records, we determined the baseline prevalence of cardio-
vascular disease (International Classification of Diseases,
Clinical Modification [ICD-9-CM; www.icd9data.com/
2007/Volume1/240-279/250-259/250/default.htm] codes
410.xx–414.xx, 430.xx–432.xx, 434.xx–436.xx, 437.1,
440.xx, 441.xx, 444.xx, 437.0 and 443.81, and revascular-
isation codes 36.01, 36.02, 36.05, 36.09 and 36.1x), heart
failure (428.xx) and depression (296.2, 296.3, 300.4, 309.1
and 311). We also identified chronic kidney disease
(estimated glomerular filtration rate <60 ml min−1
1.73 m−2) from serum creatinine values using the modified
Modification of Diet in Renal Disease (MDRD) equation.
All participants were followed for up to 5 years from the
index date for new onset of diabetes, defined as an inpatient
or outpatient diagnosis (ICD-9-CM codes 250.xx), a
dispensing of an anti-hyperglycaemic medication, or two
fasting plasma glucose results >7.0 mmol/l. For each
condition, we compared the incidence of diabetes per
1,000 person-years among those with and without the
conditions. To isolate the independent contributions of the
conditions, we adjusted the incidence rates for age, sex,
baseline measures of fasting glucose, body mass index,
systolic blood pressure, triacylglycerol, HDL-cholesterol,
smoking and the presence of the other health conditions in
question. For example, when comparing those with and
without CVD, we adjusted for the presence of heart failure,
chronic kidney disease and depression in addition to age,
sex and the metabolic variables. To account for potential
ascertainment bias, we further adjusted for the number of
fasting glucose tests performed during follow-up. All
analyses were conducted with SAS version 8.2 (SAS, Cary,
NC, USA), using Poisson regression for incidence densi-
ties, a feature of PROC GENMOD that uses time to event
(or follow-up time) as an offset variable and allows
multivariable adjustment of incidence estimates. The study
was reviewed and approved by the Institutional Review
Board of Kaiser Permanente Northwest with a waiver of
informed consent.
Results
Within 5 years of follow-up, 6.1% (n=3,537) of the study
sample developed diabetes (Table 1). These patients were
older and more likely to be men, non-white and to smoke
compared with patients who did not develop diabetes.
Baseline metabolic variables (fasting glucose, body mass
index, systolic blood pressure, triacylglycerol and HDL-
cholesterol) were all significantly more adverse among
those who developed diabetes than among those who did
not. In addition, CVD, heart failure, chronic kidney disease
and depression were all significantly more prevalent at
baseline among patients who subsequently developed
Developed diabetes No diabetes p value
n (%) 3,527 (6.1%) 54,529 (93.9%) –
Mean age (years) 58.7 (11.3) 56.8 (12.0) <0.0001
Men 51.5% 44.1% <0.0001
Non-white 10.1% 8.2% <0.0001
Current smoker 14.5% 12.4% <0.0001
Metabolic variables
Fasting plasma glucose (mmol/l) 6.0 (0.8) 5.2 (0.5) <0.0001
Body mass index (kg/m2) 34.3 (7.2) 29.6 (6.2) <0.0001
Systolic blood pressure (mmHg) 137 (18) 130 (18) <0.0001
HDL-cholesterol (mmol/l) 1.2 (0.3) 1.4 (0.4) <0.0001
Triacylglycerol (mmol/l) 2.3 (1.8) 1.6 (1.2) <0.0001
Complications (%)
Cardiovascular disease 21.6 13.0 <0.0001
Heart failure 5.5 2.0 <0.0001
Chronic kidney disease 9.9 7.1 <0.0001
Depression 24.0 20.4 <0.0001
Mean number of fasting glucose tests
during follow-up
2.7 (2.0) 2.4 (2.0) <0.0001
Table 1 Baseline characteristics
of patients who did and
did not develop diabetes within
5 years
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diabetes compared with those who did not. Patients who
developed diabetes had slightly more fasting glucose tests
on average than those who did not develop diabetes.
Figure 1 displays the adjusted cumulative incidence of
diabetes for patients with CVD (panel a), heart failure
(panel b), chronic kidney disease (panel c) and depression
(panel d). After adjustment for all other risk factors, patients
with CVD developed diabetes at a rate of 11.9/1,000 person-
years (95% CI 10.9–13.0), compared with 8.8 (95% CI 8.4–
9.3) among patients without CVD, for an increased risk of
35% (RR 1.35, 95% CI 1.23–1.48). Heart failure was
associated with an increase in the risk of diabetes of 48%
(RR 1.48, 95% CI 1.27–1.73). Depression was independently
associated with an increase in the risk of diabetes of 10% (RR
1.10, 95% CI 1.02–1.20). The relationship between chronic
kidney disease and diabetes did not reach statistical signifi-
cance (RR 1.10, 95% CI 0.97–1.24).
Discussion
To our knowledge, no studies to date have simultaneously
analysed cardiovascular disease, heart failure, chronic
kidney disease and depression as predictors of incident
diabetes while also controlling for known metabolic predic-
tors of diabetes risk. The complex interplay between
cardiometabolic risk factors, such as hyperglycaemia, obesity,
hypertension, dyslipidaemia and diabetes and its complica-
tions, requires a large sample with sufficient follow-up to
isolate the independent contributions of each factor. In this
observational cohort study of 58,056 non-diabetic patients,
we found that the presence of each of these complications
increased the risk of developing diabetes independently of one
another and of other known risk factors.
Cardiovascular disease is recognised as an independent
risk factor for diabetes [3]. Heart failure has also been
shown to increase the risk of diabetes [4], as has depression
[5]. Although each of these studies reported higher risks
than we found, this was probably due to insufficient control
for known risk factors, such as fasting glucose, or for health
conditions other than those being tested. Indeed, our results
were stronger in models that did not include metabolic
variables or the other health conditions (data not shown).
Thus, our results probably represent a more accurate
estimate of the independent contributions to diabetes risk
of CVD, heart failure, kidney disease and depression.
Fig. 1 Cumulative incidence of diabetes by presence (dashed line) or
absence (continuous line) of CVD (a; RR 1.35 [95% CI 1.23–1.48]),
heart failure (b; RR 1.48 [95% CI 1.27–1.73]), renal disease (c; RR
1.10 [0.97–1.24] and depression (d; RR 1.10 [95% CI 1.02–1.20]).
Analyses are adjusted for age, sex, body mass index, fasting glucose,
systolic blood pressure, triacylglycerol, HDL-cholesterol, smoking
and the presence of the other conditions shown
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In addition to the observational study design, our study
has several limitations. First, the data are limited by the
inclusion of only clinic attendees who had the necessary
metabolic variables measured and the opportunity for
assessment of the health conditions we analysed. It is
possible that non-attendees without the necessary measure-
ments were less likely to have the studied conditions, and
were also at lower risk of developing diabetes. If so, the
incidence rates we report for patients without the conditions
could be overestimated. However, it is also possible that the
risk of developing diabetes would be unaffected if the
relative relationship between the conditions studied and
diabetes is the same in attendees and non-attendees.
Second, we assessed the presence of CVD, heart failure,
renal disease and depression at baseline. We did not attempt
to account for the development of these conditions prior to
diabetes onset. If patients who developed the conditions
were at an elevated risk of diabetes similar to the risk in
those who had the conditions at baseline, this higher risk
would have been mis-assigned to those without the
conditions, which would have resulted in underestimation
of the relative risk. Though this is speculative, we believe
that, for this reason, the relative risks of incident diabetes
associated with the studied conditions are conservative.
Third, patients with the studied conditions received fasting
glucose tests somewhat more frequently, thereby increasing
their opportunity for a diabetes diagnosis. Although our
estimates adjusted for the number of follow-up tests, some
unmeasured ascertainment bias might remain. Finally, our
assessment of diabetes status both at baseline (as an
exclusion criterion) and at follow-up (as the outcome
measure) did not include oral glucose tolerance tests.
Therefore, some patients with clinical diabetes but with
fasting glucose <7 mmol/l were probably included in the
study, while others may have developed clinical diabetes
but remained undetected because of subdiagnostic fasting
glucose levels. We cannot determine how this limitation
would have affected our results.
Lifestyle interventions have been repeatedly shown to
prevent or delay the onset of type 2 diabetes in at-risk
individuals [6], and also improve CVD risk factors [7].
Furthermore, the benefits of early intervention last well
beyond the duration of the intervention itself [8–10]. Of
course, the presence of serious comorbidities, such as those
we examined, may reduce patients’ willingness or ability to
engage in intensive exercise programmes. In any case, the
bidirectional relationship between diabetes and its compli-
cations calls for accurate assessment of health risk well
before diabetes onset so that the maximum benefits of early
intervention can be realised. Furthermore, it is possible that
primary prevention of CVD and other complications will
reduce the risk of subsequent diabetes.
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